Clinical trial
Amonafide in Combination With Cytarabine in Secondary AML
NCT00273884 · Xanthus Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00273884 |
|---|---|
| Title | Amonafide in Combination With Cytarabine in Secondary AML |
| Official title | Phase 2 Open-Label Study of Amonafide L-Malate in Combination With Cytarabine in Subjects With Secondary Acute Myeloid Leukemia (AML) |
| Lead sponsor | Xanthus Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Amonafide L-Malate, Cytarabine |
| Enrollment | 80 |
| Start date | Aug 1, 2005 |
| Completion | Apr 1, 2009 |
| First posted | Jan 9, 2006 |
| Last update posted | Feb 19, 2007 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: